EZH2 as a Potential Target in Diffuse Large B Cell Lymphoma
Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B cell lymphoma
Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B cell lymphoma (DLBCL).
Clinical Pearls:
- EZH2 is an epigenetic modifier protein that forms part of the so-called polycomb complex 2 that was found to be highly expressed in DLBCL
- Studies have shown that EZH2 functions to suppress checkpoints that stops cells from dividing
- EZH2 is frequently mutated in the GCB-type DLBCL tumors and in follicular lymphomas, supercharging the protein
- The mutation adds three methyl groups to the tails of histone 3 lysine 27, which causes the repression of proliferation checkpoint regulatory genes and genes involved in the differentiation of B cells
- The supercharged EZH2 blocks the ability of germinal center B cells to differentiate, causing the cells to continue to divide
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
